Related Stories
Progress
For Sopharma AD this effort is another contribution to an excellent corporate governance file.
Becoming a strong regional player and the first partnering choice
Expanding the product portfolio will strenghten the growth potential.
Grow organically in selected new markets to become a strong regional player with stable, geographically diversified revenues by:
Maintain the Company’s position as a leading Bulgarian pharmaceutical manufacturer with high quality affordable products and improve existing products.
Documentation for registration of 2 medicinal products has been submitted:- Carsil Max 110 mg capsules (Tajikistan).License: - Nexopral 20 mg gastro-resistant tablets (Bulgaria).
Further consolidate and integrate the Group to optimize its cost structure, control entirely the production chain and benefit from potential synergies.